| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10009167 | HBV | ENSG00000183873.20 | protein_coding | SCN5A | No | No | 6331 | E9PG18 E9PHB6 H9KVD2 K4DIA1 Q14524 Q86V90 |
| TVIS20012030 | HPV | ENSG00000183873.20 | protein_coding | SCN5A | No | No | 6331 | E9PG18 E9PHB6 H9KVD2 K4DIA1 Q14524 Q86V90 |
| TVIS20036049 | HPV | ENSG00000183873.20 | protein_coding | SCN5A | No | No | 6331 | E9PG18 E9PHB6 H9KVD2 K4DIA1 Q14524 Q86V90 |
| TVIS20056806 | HPV | ENSG00000183873.20 | protein_coding | SCN5A | No | No | 6331 | E9PG18 E9PHB6 H9KVD2 K4DIA1 Q14524 Q86V90 |
| TVIS44025067 | HTLV-1 | ENSG00000183873.20 | protein_coding | SCN5A | No | No | 6331 | E9PG18 E9PHB6 H9KVD2 K4DIA1 Q14524 Q86V90 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | SCN5A |
|---|---|
| DrugBank ID | DB00379 |
| Drug Name | Mexiletine |
| Target ID | BE0000197 |
| UniProt ID | Q14524 |
| Regulation Type | inhibitor |
| PubMed IDs | 12123767; 12604879; 12650887; 12676070; 16168489; 11196553; 11752352 |
| Citations | Valdivia CR, Ackerman MJ, Tester DJ, Wada T, McCormack J, Ye B, Makielski JC: A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine. Cardiovasc Res. 2002 Aug 1;55(2):279-89.@@Chinushi M, Tagawa M, Sugiura H, Komura S, Hosaka Y, Washizuka T, Aizawa Y: Ventricular tachyarrhythmias in a canine model of LQT3: arrhythmogenic effects of sympathetic activity and therapeutic effects of mexiletine. Circ J. 2003 Mar;67(3):263-8.@@Fabritz L, Kirchhof P, Franz MR, Nuyens D, Rossenbacker T, Ottenhof A, Haverkamp W, Breithardt G, Carmeliet E, Carmeliet P: Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in DeltaKPQ SCN5A (long QT3) mice. Cardiovasc Res. 2003 Mar 15;57(4):1085-93.@@Wang HW, Zheng YQ, Yang ZF, Li CZ, Liu YM: Effect of mexiletine on long QT syndrome model. Acta Pharmacol Sin. 2003 Apr;24(4):316-20.@@Napolitano C, Bloise R, Priori SG: Gene-specific therapy for inherited arrhythmogenic diseases. Pharmacol Ther. 2006 Apr;110(1):1-13. Epub 2005 Sep 15.@@Shimizu W, Antzelevitch C, Suyama K, Kurita T, Taguchi A, Aihara N, Takaki H, Sunagawa K, Kamakura S: Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
| Groups | Approved; Investigational |
| Direct Classification | Phenol ethers |
| SMILES | CC(N)COC1=C(C)C=CC=C1C |
| Pathways | Mexiletine Action Pathway |
| PharmGKB | PA450488 |
| ChEMBL | CHEMBL558 |
